GW on fire: PhIII epilepsy data signals success ahead for first CBD drug
Image: Justin Gover, GW Pharma
The British company shooting to be the first to launch a drug derived from the cannabis plant just got a big nod from the scientific community, paving the way for what could be one of the biggest blockbuster launches of the year.
Peer-reviewed journal The Lancet published Phase III data on GW Pharmaceuticals’ cannabidiol med Epidiolex, which was studied in a kind of pediatric epilepsy called Lennox-Gastaut syndrome (LGS).
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.